AG Sessions seeks repeal of Rohrabacher-Farr Amendment

by Thompson Coburn LLP

Thompson Coburn LLP

Since the new Presidential administration took office late last year, the cannabis industry has received a mixed set of signals from this administration as to how it will treat the growing cannabis industry in relation to the Controlled Substances Act (CSA). In March 2017, Tracking Cannabis described a set of comments by Attorney General Sessions in which he indicated his strong skepticism regarding the legalization of recreational cannabis. Sessions stated:

I’ve said before that the President understands the pain and suffering that many people go through who are facing especially terminal diseases and the comfort that some of these drugs, including medical marijuana, can bring to them. And that's one that Congress ... put in an appropriations bill saying the Department of Justice wouldn’t be funded to go after those folks.

There is a big difference between that and recreational marijuana. And I think that when you see something like the opioid addiction crisis blossoming in so many states around this country, the last thing that we should be doing is encouraging people. There is still a federal law that we need to abide by in terms of ... recreational marijuana and other drugs of that nature.

So I think there’s a big difference between medical marijuana ... in accordance with the [the Rohrabacher-Farr Amendment], have set forth a process to administer and regulate that usage, versus recreational marijuana. That’s a very, very different subject.

This statement seemed to indicate that the Attorney General was willing to adhere to the Rohrabacher-Farr Amendment, focusing the DOJ’s cannabis enforcement efforts on recreational cannabis, rather than medical cannabis-related activities. However, a few weeks later, AG Sessions revisited the topic of enforcement against recreational cannabis, stating that the Cole Memorandum (indicating that the DOJ will not engage in enforcement activities against individuals operating legally under state cannabis programs in those states) is “valid,” and that the DOJ is not “able to go into a state and pick up the work that police and sheriffs have been doing for decades.”

These statements appeared to alleviate fears in the industry that the Cole Memorandum would be disregarded.

The Rohrabacher-Farr Amendment and a pivoting administration

On May 5, 2017, President Trump signed a budget bill that contained a one year extension of the Rohrabacher-Farr Amendment that not only extended its effective time periods, but extended it to those states and U.S. territories that have passed legalized medical cannabis programs. However, in doing so, the President issued a “signing statement” commenting on the amendment:

Division B, section 537 provides that the Department of Justice may not use any funds to prevent implementation of medical marijuana laws by various States and territories. I will treat this provision consistently with my constitutional responsibility to take care that the laws be faithfully executed.

It is unclear what the President’s comment may indicate on a going-forward basis, but the fact that the statement was included has raised questions among members of the industry. When combined with the statements made by Attorney General Jeff Sessions, the industry continued to be hopeful that the current administration would leave the regulation of cannabis, at least medical cannabis, to the states.

However, on June 12, 2017, a letter written by AG Sessions on May 1 was released detailing his opposition to the extension of the Amendment. In the letter, addressed to Speaker of the House Paul Ryan, Senate Minority Leaders Nancy Pelosi and Charles Schumer, and Senate Majority Leader Mitch McConnell, Sessions sought to “renew the Department of Justice’s opposition to the inclusion of language in the appropriations legislation that would prohibit the use of Department of Justice funds or in any way inhibit its authority to enforce the Controlled Substances Act (CSA).” In doing so, Sessions cites to the 2016 “National Drug Threat Assessment” (a document released periodically by the DOJ outlining the state of the impact drugs have on the U.S.) for the proposition that not only does the DOJ see a “potential long-term uptick in violent crime” related to drug use, and for the fact that foreign criminal organizations are operating illegal cannabis programs in states where cannabis has been legalized. (See page 115 of the Assessment.) AG Sessions also cites to the 2016 9th Circuit case of United States v. McIntosh which enforced the Rohrabacher-Farr Amendment, prohibiting the prosecution of individuals who had not been found to be in violation of state cannabis-legalization laws.

AG Sessions’ letter, at is core, requests the repeal of the Rohrabacher-Farr Amendment, to extinguish the legal barriers between the DOJ and its ability to enforce the CSA. Maybe one of the most disturbing points of AG Sessions’ position is that he continues to reiterate that the use of cannabis is related to the opiate addiction crisis. Yet studies seem to indicate that in those states that have had a legalized cannabis program, the abuse of drugs has decreased. So to ask Congress to reverse itself on the basis of what appears to be an incorrect conclusion and, at best, broad sweeping statements in the National Drug Threat Assessment seems unreasonable. There are no known written responses to the letter from any of the recipients, however, members of the cannabis industry should keep an eye on Tracking Cannabis as the administration’s cannabis enforcement efforts continue to develop.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Thompson Coburn LLP | Attorney Advertising

Written by:

Thompson Coburn LLP

Thompson Coburn LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.